BCAT1 overexpression is an indicator of poor prognosis in patients with urothelial carcinomas of the upper urinary tract and urinary bladder. Issue 4 (13th September 2015)

• Record Type: Journal Article
• Authors: Chang, I‐Wei; Wu, Wen‐Jen; Wang, Yu‐Hui; Wu, Ting‐Feng; Liang, Peir‐In; He, Hong‐Lin; Yeh, Bi‐Wen; Li, Chien‐Feng
• Is Part Of: Histopathology. Volume 68:Issue 4(2016)
• Page Start: 520
• Page End: 532
• Publication Date: 2015-09-13
• Subjects: BCAT1 -- branched‐chain amino acid transaminase 1 -- upper urinary tract -- urinary bladder -- urothelial carcinoma; Histology, Pathological -- Periodicals; 611.018
• DOI: 10.1111/his.12778
• Languages: English
• ISSNs: 0309-0167

Abstract

Abstract : Aims: Amino acid biosynthesis is one of the cardinal events of carcinogenesis that has not been investigated in urothelial carcinoma (UC). By data‐mining a published transcriptomic database of UCs of urinary bladder (UBUCs) (GSE31684), we identified branched‐chain amino acid transaminase 1 ( BCAT1 ) as the most significantly stepwise up‐regulated gene during tumour progression among those associated with the amino acid biosynthetic process (GO:0008652). Accordingly, we analysed BCAT1 transcript and protein expression with their clinicopathological significance. Methods and results: We used real‐time reverse transcription–polymerase chain reaction (RT–PCR) to detect BCAT1 transcript levels in 20 UCs of upper tract (UTUCs) and 20 UBUCs, respectively. Immunohistochemical study was performed to determine BCAT1 protein expression in 340 UTUCs and 295 UBUCs. Higher BCAT1 transcript levels were associated with higher pT status in both groups ( P < 0.05). BCAT1 protein overexpression was also associated significantly with adverse clinicopathological features, e.g. advanced pT stage, nodal metastasis, high pathological grade, etc. ( P < 0.05). BCAT1 overexpression predicted worse disease‐specific survival and metastasis‐free survival in both univariate and multivariate analyses ( P ≤ 0.001). Conclusion: BCAT1 overexpression is associated with advanced tumour status, and implies adverse clinical outcomes of UCs, suggesting that its role in tumour progression could serve as a prognostic biomarker and a novel therapeutic target in UC.